{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:14:43Z","timestamp":1794280483944,"version":"4.9.0"},"reference-count":59,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI186784"],"award-info":[{"award-number":["R01AI186784"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-17-00014"],"award-info":[{"award-number":["AID-OAA-A-17-00014"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016820","name":"Vaccine Research Center","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100016820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Broadly neutralizing antibodies (bnAbs) are advancing as a preventative or treatment option for HIV infection, but currently must be administered parenterally, typically as a large injection or infusion, an invasive method of delivery, especially for the pediatric population. Here, we present proof-of-concept data on a minimally invasive microneedle (MN) patch platform codelivering three bnAbs, PGT121, VRC07-523LS, and PGDM1400LS, from separate MN patch units or pixels. Each 1 cm2 patch pixel, fabricated via solvent casting, contained \u223c2 mg of one bnAb. In ex vivo porcine skin tests, the MNs effectively penetrated the skin. When tested in vitro in PBS buffer, MNs quickly dissolved, fully releasing bnAbs within 10 min. VRC07-523LS and PGT121 functionality was maintained during patch manufacturing, as confirmed by an in vitro HIV-1 neutralization assay, while PGDM1400LS lost some potency. In a rat model, coadministration of 1 cm2 patch units for each bnAb resulted in systemic exposure by the first collection time point of 3 h, reaching maximal concentrations by day 3 of up to 68 \u03bcg\/mL. These preliminary findings suggest that the MN patch platform may serve as a promising alternative to injectable bnAb formulations for HIV prevention and treatment, particularly in neonates and infants, although further investigation is required to establish its clinical utility. Additionally, the solid-state MN formulation of bnAbs may eliminate the need for cold-chain storage or distribution, making the patch particularly suitable for use in resource-limited settings.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.5c01650","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:43:14Z","timestamp":1784072594000},"page":"4048-4057","source":"Crossref","is-referenced-by-count":2,"title":["Proof-of-Concept Development and Preclinical Evaluation\nof a Microarray Patch Platform for Codelivery of Multiple Broadly\nNeutralizing Antibodies for HIV Prevention"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6637-5290","authenticated-orcid":true,"given":"M. Melissa","family":"Peet","sequence":"first","affiliation":[{"name":"Macon & Joan Brock Virginia Health Sciences, Old Dominion University , , , ,","place":["Norfolk, Virginia, United States, 23507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Agrahari","sequence":"additional","affiliation":[{"name":"Macon & Joan Brock Virginia Health Sciences, Old Dominion University , , , ,","place":["Norfolk, Virginia, United States, 23507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-8973","authenticated-orcid":true,"given":"Parbeen","family":"Singh","sequence":"additional","affiliation":[{"name":"University of Connecticut , , , ,","place":["Storrs, Connecticut, United States, 06269"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam Luong Hoai","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University of Connecticut , , , ,","place":["Storrs, Connecticut, United States, 06269"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise A.","family":"Ouattara","sequence":"additional","affiliation":[{"name":"Macon & Joan Brock Virginia Health Sciences, Old Dominion University , , , ,","place":["Norfolk, Virginia, United States, 23507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sung","family":"Yang","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , , , ,","place":["Bethesda, Maryland, United States, 20814"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Herrera","sequence":"additional","affiliation":[{"name":"Macon & Joan Brock Virginia Health Sciences, Old Dominion University , , , ,","place":["Norfolk, Virginia, United States, 23507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarendra","family":"Pegu","sequence":"additional","affiliation":[{"name":"VLP Therapeutics, Inc. , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Pierson","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , , , ,","place":["Bethesda, Maryland, United States, 20814"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-4807","authenticated-orcid":true,"given":"Thanh D.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University of Connecticut , , , ,","place":["Storrs, Connecticut, United States, 06269"]},{"name":"University of Connecticut , , , ,","place":["Storrs, Connecticut, United States, 06269"]},{"name":"University of Connecticut , , , ,","place":["Storrs, Connecticut, United States, 06269"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo F.","family":"Doncel","sequence":"additional","affiliation":[{"name":"Macon & Joan Brock Virginia Health Sciences, Old Dominion University , , , ,","place":["Norfolk, Virginia, United States, 23507"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026080309073416700_cit1","volume-title":"Fact Sheet: HIV Statistics Globally and by WHO Region","author":"WHO.","year":"2025"},{"key":"2026080309073416700_cit2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1654938","article-title":"The Need\nfor Pediatric Formulations\nto Treat Children with HIV","volume":"2016","author":"Schlatter","year":"2016","journal-title":"AIDS Res. Treat."},{"issue":"10","key":"2026080309073416700_cit3","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","article-title":"Safety, tolerability,\npharmacokinetics, and\nimmunological activity of dual-combinations and triple-combinations\nof anti-HIV monoclonal antibodies PGT121, PGDM1400, 10\u20131074,\nand VRC07\u2013523LS administered intravenously to HIV-uninfected\nadults: a phase 1 randomised trial","volume":"10","author":"Sobieszczyk","year":"2023","journal-title":"Lancet HIV"},{"issue":"1","key":"2026080309073416700_cit4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","article-title":"Clinical trials of\nbroadly neutralizing\nmonoclonal antibodies in people living with HIV \u2013 a review","volume":"22","author":"Mahomed","year":"2025","journal-title":"AIDS Res. Ther."},{"issue":"1","key":"2026080309073416700_cit5","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.1038\/s41467-025-63051-8","article-title":"Hyaluronidase-enhanced\nsubcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical\ntrial in HIV-uninfected women","volume":"16","author":"Mahomed","year":"2025","journal-title":"Nat. Commun."},{"issue":"5993","key":"2026080309073416700_cit6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural\nBasis for Broad and Potent Neutralization\nof HIV-1 by Antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"2026080309073416700_cit7","doi-asserted-by":"publisher","first-page":"10844","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly\nneutralizing antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"2026080309073416700_cit8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI80561","article-title":"Towards HIV-1 remission: potential roles for broadly\nneutralizing antibodies","volume":"126","author":"Halper-Stromberg","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"20","key":"2026080309073416700_cit9","doi-asserted-by":"publisher","first-page":"10648","DOI":"10.1128\/JVI.01911-15","article-title":"Envelope Glycoprotein\nInternalization Protects Human and Simian Immunodeficiency Virus-Infected\nCells from Antibody-Dependent Cell-Mediated Cytotoxicity","volume":"89","author":"von Bredow","year":"2015","journal-title":"J. Virol."},{"issue":"1","key":"2026080309073416700_cit10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11904-025-00744-1","article-title":"Future of\nbNAbs in HIV Treatment","volume":"22","author":"Tebas","year":"2025","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"4","key":"2026080309073416700_cit11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/COH.0000000000000800","article-title":"Divide and conquer:\nbroadly neutralizing antibody combinations\nfor improved HIV-1 viral coverage","volume":"18","author":"Wagh","year":"2023","journal-title":"Curr. Opin.\nHIV AIDS"},{"issue":"3","key":"2026080309073416700_cit12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies\nfor Prevention and Treatment of HIV-1 Clade C Infection","volume":"12","author":"Wagh","year":"2016","journal-title":"PLoS Pathog."},{"key":"2026080309073416700_cit13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines\nand Broadly\nNeutralizing Antibodies for HIV-1 Prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"2026080309073416700_cit14","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization\ntiter biomarker for antibody-mediated\nprevention of HIV-1 acquisition","volume":"28","author":"Gilbert","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"2026080309073416700_cit15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1208\/s12249-015-0288-y","article-title":"Tolerability\nof High-Volume Subcutaneous Injections of a Viscous Placebo Buffer:\nA Randomized, Crossover Study in Healthy Subjects","volume":"16","author":"Dias","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"2026080309073416700_cit16","doi-asserted-by":"publisher","first-page":"115326","DOI":"10.1016\/j.addr.2024.115326","article-title":"Long-acting transdermal drug delivery\nformulations: Current developments and innovative pharmaceutical approaches","volume":"210","author":"Karve","year":"2024","journal-title":"Adv. Drug Delivery Rev."},{"issue":"14","key":"2026080309073416700_cit17","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","article-title":"Microneedles\nfor drug and vaccine\ndelivery","volume":"64","author":"Kim","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"2026080309073416700_cit18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/pharmaceutics15010277","article-title":"Microneedle-Mediated\nTransdermal Delivery of Biopharmaceuticals","volume":"15","author":"Nguyen","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10095","key":"2026080309073416700_cit19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","article-title":"The safety,\nimmunogenicity, and acceptability of inactivated\ninfluenza vaccine delivered by microneedle patch (TIV-MNP 2015): a\nrandomised, partly blinded, placebo-controlled, phase 1 trial","volume":"390","author":"Rouphael","year":"2017","journal-title":"Lancet"},{"issue":"10439","key":"2026080309073416700_cit20","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(24)00532-4","article-title":"A measles and rubella\nvaccine microneedle patch in\nThe Gambia: a phase 1\/2, double-blind, double-dummy, randomised, active-controlled,\nage de-escalation trial","volume":"403","author":"Adigweme","year":"2024","journal-title":"Lancet"},{"key":"2026080309073416700_cit21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jconrel.2019.10.022","article-title":"Polymeric microneedles\nfor controlled transdermal drug\ndelivery","volume":"315","author":"Singh","year":"2019","journal-title":"J. Controlled Release"},{"key":"2026080309073416700_cit22","doi-asserted-by":"publisher","first-page":"123814","DOI":"10.1016\/j.ijpharm.2024.123814","article-title":"Accelerated cascade\nmelanoma therapy using enzyme-nanozyme-integrated\ndissolvable polymeric microneedles","volume":"652","author":"Singh","year":"2024","journal-title":"Int. J.\nPharm."},{"issue":"5","key":"2026080309073416700_cit23","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202300519","article-title":"It Takes Two\nto Tangle: Microneedle Patches Co-delivering Monoclonal Antibodies\nand Engineered Antimicrobial Peptides Effectively Eradicate Wound\nBiofilms","volume":"24","author":"Su","year":"2024","journal-title":"Macromol. Biosci."},{"issue":"5","key":"2026080309073416700_cit24","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1021\/acs.molpharmaceut.2c00919","article-title":"Single-Administration\nLong-Acting Microarray\nPatch with Ultrahigh Loading Capacity and Multiple Releases of Thermally\nStable Antibodies","volume":"20","author":"Tran","year":"2023","journal-title":"Mol. Pharmaceutics"},{"issue":"8","key":"2026080309073416700_cit25","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1021\/acs.molpharmaceut.8b00544","article-title":"Microneedle-Mediated\nTransdermal Delivery of Bevacizumab","volume":"15","author":"Courtenay","year":"2018","journal-title":"Mol. Pharmaceutics"},{"issue":"11","key":"2026080309073416700_cit26","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1021\/acsmaterialslett.4c01164","article-title":"Carrier Polymer-Free\nDissolvable Microneedles Enable Superhigh Drug Payload for Percutaneous\nProtein Delivery","volume":"6","author":"Wang","year":"2024","journal-title":"ACS Mater. Lett."},{"key":"2026080309073416700_cit27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jconrel.2015.10.002","article-title":"IgG-loaded\nhyaluronan-based dissolving microneedles\nfor intradermal protein delivery","volume":"218","author":"Mo\u0308nka\u0308re","year":"2015","journal-title":"J. Controlled\nRelease"},{"issue":"9","key":"2026080309073416700_cit28","doi-asserted-by":"publisher","first-page":"2400028","DOI":"10.1002\/adtp.202400028","article-title":"Single-Administration\nSelf-Boosting\nMicroneedle Patch for the Treatment of Obesity","volume":"7","author":"Singh","year":"2024","journal-title":"Adv. Therapeut."},{"key":"2026080309073416700_cit29","doi-asserted-by":"publisher","first-page":"2200905","DOI":"10.1002\/admt.202200905","article-title":"A Single-Administration\nMicroneedle Skin Patch for Multi-Burst Release of Vaccine against\nSARS-CoV-2","volume":"8","author":"Tran","year":"2022","journal-title":"Adv. Mater. Technol."},{"issue":"9","key":"2026080309073416700_cit30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41551-020-00650-4","article-title":"Transdermal microneedles for the programmable burst\nrelease of multiple vaccine payloads","volume":"5","author":"Tran","year":"2021","journal-title":"Nat. Biomed.\nEng."},{"issue":"10","key":"2026080309073416700_cit31","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1007\/s13346-025-01854-4","article-title":"Enhancing vaccine stability in transdermal\nmicroneedle platforms","volume":"15","author":"Pahal","year":"2025","journal-title":"Drug Delivery Transl.\nRes."},{"issue":"12","key":"2026080309073416700_cit32","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral\neffect of a triple combination of HIV-1 broadly neutralizing antibodies:\na phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat. Med."},{"issue":"21","key":"2026080309073416700_cit33","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced\npotency of a broadly neutralizing\nHIV-1 antibody in vitro improves protection against lentiviral infection\nin vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"issue":"1","key":"2026080309073416700_cit34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40486-024-00204-2","article-title":"Engineering\nmicroscopic\ndelivery systems: a review of dissolving microneedle design, fabrication,\nand function","volume":"12","author":"Dave","year":"2024","journal-title":"Micro Nano Syst. Lett."},{"issue":"50","key":"2026080309073416700_cit35","doi-asserted-by":"publisher","first-page":"13018","DOI":"10.1021\/acs.jpcb.5c06203","article-title":"Thermodynamic\nBasis of Sugar-Dependent Polymer Stabilization: Informing Biologic\nFormulation Design","volume":"129","author":"Muralikrishnan","year":"2025","journal-title":"J. Phys. Chem. B"},{"issue":"13","key":"2026080309073416700_cit36","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.addr.2011.07.006","article-title":"Protein-excipient\ninteractions: mechanisms and biophysical characterization applied\nto protein formulation development","volume":"63","author":"Kamerzell","year":"2011","journal-title":"Adv. Drug\nDeliv. Rev."},{"issue":"10","key":"2026080309073416700_cit37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/gels9100806","article-title":"Dissolving and Swelling Hydrogel-Based\nMicroneedles: An Overview of Their Materials, Fabrication, Characterization\nMethods, and Challenges","volume":"9","author":"Shriky","year":"2023","journal-title":"Gels"},{"issue":"18","key":"2026080309073416700_cit38","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.3390\/polym16182568","article-title":"Polymeric\nMicroneedle Drug Delivery Systems: Mechanisms of Treatment, Material\nProperties, and Clinical Applications-A Comprehensive Review","volume":"16","author":"Liu","year":"2024","journal-title":"Polymers"},{"key":"2026080309073416700_cit39","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202504342","article-title":"Microneedles\nBased Thermally Stable Ad-5 Viral Vector\nfor Vaccine Delivery","volume":"15","author":"Singh","year":"2026","journal-title":"Adv. Healthc Mater."},{"issue":"3","key":"2026080309073416700_cit40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41551-018-0337-4","article-title":"Rapidly separable microneedle patch for the sustained\nrelease of a contraceptive","volume":"3","author":"Li","year":"2019","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"2026080309073416700_cit41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/pharmaceutics12020152","article-title":"Alternatives\nto Biological Skin in Permeation Studies: Current Trends and Possibilities","volume":"12","author":"Neupane","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"2026080309073416700_cit42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.yrtph.2009.03.012","article-title":"Immunogenicity\nof biologically-derived\ntherapeutics: assessment and interpretation of nonclinical safety\nstudies","volume":"54","author":"Ponce","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"2026080309073416700_cit43","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/infdis\/jiac041","article-title":"Safety and Pharmacokinetics of Monoclonal Antibodies\nVRC07\u2013523LS and PGT121 Administered Subcutaneously for Human\nImmunodeficiency Virus Prevention","volume":"226","author":"Mahomed","year":"2022","journal-title":"J. Infect.\nDis."},{"issue":"2","key":"2026080309073416700_cit44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13346-016-0282-2","article-title":"Long-term stability\nof influenza vaccine in a dissolving microneedle patch","volume":"7","author":"Mistilis","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"key":"2026080309073416700_cit45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.biomaterials.2015.04.007","article-title":"Clinical study and stability\nassessment of\na novel transcutaneous influenza vaccination using a dissolving microneedle\npatch","volume":"57","author":"Hirobe","year":"2015","journal-title":"Biomaterials"},{"issue":"2","key":"2026080309073416700_cit46","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00152-22","article-title":"Broadly neutralizing\nantibodies for HIV prevention: a comprehensive review and future perspectives","volume":"37","author":"Mahomed","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"2026080309073416700_cit47","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1038\/s41467-023-41966-4","article-title":"Mucosal application\nof the broadly neutralizing antibody 10\u20131074 protects macaques\nfrom cell-associated SHIV vaginal exposure","volume":"14","author":"Suphaphiphat","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"2026080309073416700_cit48","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.virol.2012.06.025","article-title":"Topical gel formulation\nof broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers\nprotection against HIV-1 vaginal challenge in a humanized mouse model","volume":"432","author":"Veselinovic","year":"2012","journal-title":"Virology"},{"issue":"7","key":"2026080309073416700_cit49","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02465-16","article-title":"Pharmacokinetics\nand Preliminary Safety of\nPod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N\nfor HIV Prophylaxis in a Macaque Model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"3","key":"2026080309073416700_cit50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ymthe.2020.01.002","article-title":"Aerosol Delivery of Synthetic mRNA to Vaginal Mucosa\nLeads to Durable Expression of Broadly Neutralizing Antibodies against\nHIV","volume":"28","author":"Lindsay","year":"2020","journal-title":"Mol. Ther."},{"issue":"6","key":"2026080309073416700_cit51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004329","article-title":"Safety and pharmacokinetics\nof VRC07\u2013523LS\nadministered via different routes and doses (HVTN 127\/HPTN 087): A\nPhase I randomized clinical trial","volume":"21","author":"Walsh","year":"2024","journal-title":"PLoS Med."},{"issue":"3","key":"2026080309073416700_cit52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/antib9030036","article-title":"Characterization\nof\nCo-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal\nAntibodies for Subcutaneous Administration","volume":"9","author":"Sharma","year":"2020","journal-title":"Antibodies"},{"issue":"1","key":"2026080309073416700_cit53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1186\/s12879-024-09588-3","article-title":"Safety\nand pharmacokinetics of subcutaneous administration\nof broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs),\ngiven to HIV-1 exposed, uninfected neonates and infants: study protocol\nfor a phase I trial","volume":"24","author":"Goga","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"2026080309073416700_cit54","doi-asserted-by":"publisher","first-page":"2025.05.27.656504","DOI":"10.1101\/2025.05.27.656504","article-title":"Engineering\nSustained-Release Broadly Neutralizing\nAntibody Formulations","author":"Jons","year":"2025","journal-title":"bioRxiv"},{"key":"2026080309073416700_cit55","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.actbio.2025.02.035","article-title":"Subcutaneous liposomal delivery improves monoclonal\nantibody pharmacokinetics in vivo","volume":"195","author":"Karimi","year":"2025","journal-title":"Acta Biomater."},{"issue":"4","key":"2026080309073416700_cit56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/jpm9040049","article-title":"A Perspective\non Microneedle-Based Drug Delivery and Diagnostics in Paediatrics","volume":"9","author":"Pires","year":"2019","journal-title":"J. Pers. Med."},{"key":"2026080309073416700_cit57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejpb.2019.01.005","article-title":"Recent advances\nin microneedle-based\ndrug delivery: Special emphasis on its use in paediatric population","volume":"136","author":"Duarah","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"2026080309073416700_cit58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijpharm.2008.10.008","article-title":"In vitro\ntransdermal delivery of therapeutic antibodies using maltose microneedles","volume":"368","author":"Li","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"11","key":"2026080309073416700_cit59","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1002\/jps.23724","article-title":"Effect of microneedle geometry and supporting substrate\non microneedle\narray penetration into skin","volume":"102","author":"Kochhar","year":"2013","journal-title":"J. Pharm. Sci."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5c01650","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4048\/65945445\/acs.molpharmaceut.5c01650.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4048\/65945445\/acs.molpharmaceut.5c01650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:09:08Z","timestamp":1785762548000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4048\/5210144\/Proof-of-Concept-Development-and-Preclinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01650","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}